A natriuretic peptides clearance receptor's agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure

作者：Egom Emmanuel Eroume^*; Feridooni Tiam; Pharithi Rebabonye B; Khan Barkat; Shiwani Haaris A; Maher Vincent; El Hiani Yassine; Pasumarthi Kishore B S; Ribama Hilaire A

来源：Biomedicine & Pharmacotherapy, 2017, 93: 1144-1150.

DOI：10.1016/j.biopha.2017.07.027

• Pulmonary hypertension
• Left ventricular heart failure
• Ring-deleted atrial natriuretic peptide
• analogue

Background: In patients with left ventricular heart failure (HF), the development of pulmonary hypertension (PH) is common and represents a strong predictor of death. Despite recent advances in the pathophysiological understanding there is as yet no prospect of cure of this deadly clinical entity and the majority of patients continue to progress to right ventricular failure and die. Furthermore, there is no single medical treatment currently approved for PH related to HF. There is, therefore an urgent unmet need to identify novel pharmacological agents that will prevent the progressive increased or reverse the elevated pulmonary arterial pressures while enhancing cardiac performance in HF.
Method and results: We here reported, for the first time, using a pressure-loop (P-V) conductance catheter system, that a specific natriuretic peptides clearance receptors' agonist, the ring-deleted atrial natriuretic peptide analogue, cANF4-23 (cANF) reduces pulmonary artery pressures. Strikingly, the administration of the cANF in these mice decreased the RVSP by 50% (n = 5, F 25.687, DF 14, p < 0.001) and heart rate (HR) by 11% (n = 5, F 25.69, DF 14, p < 0.001) as well as enhancing cardiac performance including left ventricular contractility in mice. Most strikingly, mice lacking NPR- C were much more susceptible to develop HF, indicating that NPR- C is a critical protective receptor in the heart.
Conclusion: Natriuretic peptides clearance receptors' agonists may, therefore represent a novel and attractive therapeutic strategy for PH related to HF, and ultimately improves the life expectancy and quality for millions of people around the planet.

• 出版日期2017-9